Valuation: Medpace Holdings, Inc.

Capitalization 12.11B 10.28B 9.41B 8.87B 16.55B 1,154B 16.68B 112B 43.56B 549B 45.43B 44.48B 1,901B P/E ratio 2026 *
24.9x
P/E ratio 2027 * 23x
Enterprise value 10.95B 9.29B 8.51B 8.02B 14.96B 1,043B 15.08B 101B 39.38B 497B 41.08B 40.21B 1,719B EV / Sales 2026 *
3.95x
EV / Sales 2027 * 3.67x
Free-Float
80.38%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week+0.45%
Current month+0.06%
1 month-16.43%
3 months-1.19%
6 months-30.50%
Current year-25.42%
1 week 413.35
Extreme 413.35
435.15
1 month 373
Extreme 373
530.97
Current year 373
Extreme 373
628.92
1 year 284.48
Extreme 284.48
628.92
3 years 197.39
Extreme 197.39
628.92
5 years 126.94
Extreme 126.945
628.92
10 years 21.76
Extreme 21.76
628.92
Manager TitleAgeSince
Chief Executive Officer 69 1992-06-30
Director of Finance/CFO 51 2021-07-31
President 51 2021-07-31
Director TitleAgeSince
Chairman 69 1992-06-30
Director/Board Member 55 2016-06-30
Director/Board Member 72 2016-06-30
Change 5d. change 1-year change 3-years change Capi.($)
-1.18%+0.45%+33.52%+99.94% 12.11B
-0.25%+0.54%-16.33%-16.47% 43.39B
-0.37%+5.41%+34.29%+28.06% 34.7B
+1.08%-3.14%+242.05%+459.13% 30.15B
-2.04%+8.15%+11.48%-8.33% 29.83B
-3.58%-4.59%+25.92%+23.61% 28.46B
+0.30%+4.35% - - 14.82B
-4.54%+2.69%+127.14%+4,309.83% 14.48B
+0.51%+0.89%+127.02%+113.88% 12.51B
-1.38%+1.14%+4.24%-3.43% 12.29B
Average -1.14%+2.99%+65.48%+556.25% 23.27B
Weighted average by Cap. -1.02%+3.27%+58.50%+364.92%

Financials

2026 *2027 *
Net sales 2.77B 2.35B 2.15B 2.03B 3.79B 264B 3.82B 25.54B 9.97B 126B 10.4B 10.18B 435B 2.9B 2.46B 2.26B 2.13B 3.97B 276B 4B 26.75B 10.44B 132B 10.89B 10.66B 456B
Net income 492M 418M 382M 361M 673M 46.89B 678M 4.54B 1.77B 22.33B 1.85B 1.81B 77.28B 533M 453M 415M 391M 729M 50.83B 735M 4.92B 1.92B 24.21B 2B 1.96B 83.77B
Net Debt -1.16B -986M -903M -851M -1.59B -111B -1.6B -10.7B -4.18B -52.7B -4.36B -4.27B -182B -1.47B -1.25B -1.14B -1.08B -2.01B -140B -2.03B -13.55B -5.29B -66.73B -5.52B -5.4B -231B
Logo Medpace Holdings, Inc.
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Employees
6,300
Date Price Change Volume
26-05-11 418.20 $ -1.37% 162,272
26-05-08 424.00 $ -1.10% 291,516
26-05-07 428.71 $ +0.45% 346,709
26-05-06 426.79 $ -0.82% 356,511
26-05-05 430.32 $ +3.19% 421,432
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
424.00USD
Average target price
442.83USD
Spread / Average Target
+4.44%

Quarterly revenue - Rate of surprise